Skip to main content

bioMérieux S.A. (BIM.PA)

Euronext Healthcare Medical - Diagnostics & Research
57.8Fair

ValueMarkers Composite Index

Top 72%#12,631 of 45,190
Undervalued

32% below intrinsic value ($161)

UndervaluedFair ValueOvervalued
Piotroski
6/9
Neutral
Beneish
-2.74
Low Risk
Altman
5.89
Safe
DCF Value
$161
Undervalued
ROIC
6.3%
Low
P/E
27.8
Growth
Updated: ·Source: Data sourced from SEC filings and institutional providers. Not financial advice.·Report data issue

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems, which use biological samples to diagnose infectious diseases, cardiovascular pathologies, and various cancers; and microbiological testing of manufacturing primarily for food, pharmaceutical, cosmetics, and veterinary sectors. It serves clinical and hospital laboratories, physicians, blood banks, and industrial control laboratories. The company was formerly known as B-D Mérieux. bioMérieux S.A. was founded in 1963 and is headquartered in Marcy l'Etoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

CEO: Pierre Boulud14,147 employeesFRwww.biomerieux.com

Deep Dive Analysis

Weekly Stock Analysis - Free

5 undervalued stocks, fully modeled. Every Monday. No spam.

Cookie Preferences

We use cookies to analyze site usage and improve your experience. You can accept all, reject all, or customize your preferences.